+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
P

Actively Recruiting

Researchers are studying the effectiveness of dotinurad compared to allopurinol in lowering serum uric acid levels in adults with tophaceous gout. This Phase 3, randomized, double-blind trial focuses on adults aged 18 to 75 years diagnosed with gout for at least one year who have measurable tophi. The study aims to evaluate how well dotinurad lowers uric acid at Week 24 compared to allopurinol. Participants are divided into two groups. One group stops their current allopurinol and takes study-provided allopurinol once daily up to Week 76. The other group stops their prior allopurinol and starts dotinurad, beginning with 1 mg daily for the first 4 weeks, increasing to 2 mg daily for 8 weeks, then 4 mg daily through Week 76. Both treatments involve oral capsules taken once a day. This approach allows comparison of the two drugs effects over an extended treatment period. During the study, participants will have regular assessments to monitor serum uric acid levels, tophi response, and gout flare frequency up to Week 80. Safety is tracked by recording any adverse events. Data collected will include changes in uric acid, tophi area, and flare rates. Participants remain in the study for over a year, with frequent visits for evaluations and treatment adherence checks.

Age: 18Years - 75YearsAll GendersPhase 3
96 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
E

Actively Recruiting

Researchers are studying etrasimod to evaluate its safety, how it works in the body, and its effects for treating adolescents aged 12 to less than 18 years with moderately to severely active ulcerative colitis. This is a phase 2, open-label study focused on treatment in this younger population. Participants who complete the first year of treatment may continue in a long-term extension phase lasting up to 4 more years, totaling 5 years of study involvement. Participants will take etrasimod as a tablet or granules by mouth once daily for up to 52 weeks during the initial treatment phase. Those who finish this period can join the long-term extension to continue receiving the drug under study conditions. No placebo or comparison group is used, as all participants receive etrasimod. Throughout the study, researchers will monitor participants regularly to assess clinical remission using the Modified Mayo Score at weeks 12 and 52, along with endoscopic and symptomatic improvements. Blood samples will be taken at specified times to measure drug levels in the body. Safety will be tracked by recording any adverse events. Participants may be followed for up to 5 years from enrollment, including the long-term extension period.

Age: 12Years - 17YearsAll GendersPhase 2
47 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the effectiveness, safety, and tolerability of a vaccine against Clostridioides difficile C. difficile infection in adults aged 65 years and older. The study aims to reduce the number of C. difficile infections, a serious cause of diarrhea, by comparing the vaccine to a placebo. This is a phase 3, randomized, double-blinded trial sponsored by Pfizer. Participants will receive either the C. difficile vaccine or a saline placebo, both given as shots into the upper arm muscle. The study duration varies based on the occurrence of diarrhea events related to C. difficile infection, lasting up to about three and a half years. The study may end earlier if sufficient data is collected or if the vaccine is found ineffective. Vaccination involves two doses, and participants will be closely monitored during and after vaccination. During the study, participants will have three planned clinic visits and three phone visits, followed by annual clinic visits until the study ends. If participants have three or more loose stools in 24 hours, they must save the next stool and contact the study site for infection assessment, which can occur in person or remotely. Researchers will track local and systemic reactions, adverse events, and the incidence of C. difficile infections as primary outcomes over the study period.

Age: 65Years +All GendersPhase 3
185 locations
A

Actively Recruiting

Researchers are conducting a long-term observational study to collect data on people with various non-cancerous blood disorders, including hemophilia, platelet disorders, von Willebrand disease, thrombosis, and rare bleeding disorders. The study aims to monitor the safety and effectiveness of current and new therapies over a minimum of 15 years. This data collection supports research and helps understand treatment practices and disease progression in these conditions. Participants are assigned to specific groups based on their blood disorder, such as Hemophilia, Congenital Platelet Disorders, or Rare Disorders. Some groups include detailed study arms and modules focusing on particular therapies or conditions, like gene therapy or specific drugs. Data is collected at enrollment and regularly every six months or annually, with additional visits as defined by each study arm or module. Throughout the study, participants provide health data, including treatment information, bleeding events, and medication regimens. Biospecimens may also be collected to support future research. The study tracks safety outcomes and treatment effectiveness continuously. Participation can last many years, with assessments occurring semi-annually and annually to gather comprehensive long-term data on these blood disorders.

All AgesAll Genders
76 locations
S

Actively Recruiting

Researchers are evaluating a six-week music-based binaural beats stimulation program for adults diagnosed with attention-deficithyperactivity disorder ADHD. This randomized controlled study aims to assess the feasibility, acceptability, and potential cognitive effects of the intervention compared to a control group listening to similar music without binaural beats. The study will enroll 40 adults aged 18 to 55 years with a previous ADHD diagnosis. Participants are randomly assigned to either the binaural beats stimulation group or the control group, each attending 12 supervised listening sessions over six weeks. Each session lasts 20 minutes and involves listening to music through headphones. The intervention group listens to music embedded with binaural beats, while the control group listens to similar music without these beats. Sessions occur twice weekly, and before each session, participants rest for five minutes followed by heart rate and blood pressure measurements. During the study, participants complete cognitive assessments related to attention, memory, coordination, and reasoning before and after the intervention. Researchers will evaluate changes in these cognitive outcomes along with session attendance and participant retention to understand the programs feasibility and acceptability. Participation requires 12 campus visits over six weeks, with no remote option or travel reimbursement. Completing all visits earns participants a 25 gift.

Age: 18Years - 55YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
S

Actively Recruiting

Researchers are evaluating the effects of vericiguat compared to placebo in children and adolescents with heart failure caused by left ventricular systolic dysfunction. The study aims to determine if vericiguat can better reduce levels of a heart failure marker called NT-proBNP over 16 weeks. This research is a Phase 23 clinical trial assessing efficacy, safety, and pharmacokinetics in pediatric participants. Participants receive either vericiguat or placebo daily by mouth in tablet or suspension form for 52 weeks during the Base Period. After completing this phase, eligible participants can join an optional open-label Extension Period where they receive vericiguat daily. The study incorporates a previously separate extension arm, allowing long-term follow-up of up to approximately 8 years. Throughout the study, participants will have their NT-proBNP levels measured and monitored at various time points, including baseline, Week 16, Week 52, and during the Extension Period. Researchers will also track adverse events and reasons for stopping the study drug. Additional assessments include heart failure events, pharmacokinetic measurements, and safety evaluations. The total study duration can extend up to 8 years for some participants.

Age: 29Days - 17YearsAll GendersPhase 2Phase 3
111 locations

1-10 of 19

1